Inflarx Says Data from Mid-Stage Study Suggest Safety of Vilobelimab as Autoimmune Disease Treatment
06:51 AM EDT, 05/12/2021 (MT Newswires) -- Inflarx (IFRX) said Tuesday its vilobelimab drug is safe for use as treatment of an autoimmune disease called anti-neutrophil cytoplasmic auto-antibody-associated vasculitis, based on data from its mid-stage study.
Phase 2 Ixplore trial met its primary endpoint of showing vilobelimab to be safe and well-tolerated when added to current standard of care. The study compared two different dose regimens of vilobelimab to placebo but was not powered to show statistical significance on efficacy endpoints, according to the statement.
A similar study will be conducted in Europe, with results expected by the end of 2021.
Price: 3.4900, Change: +0.02, Percent Change: +0.58